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Introduction: The combination of docetaxel and cisplatin is an
effective first-line regimen in patients with advanced non-small cell
lung cancer. However, the recommended three-weekly schedule is
associated with frequent neutropenia and infections. Because of the
toxicity of cisplatin, patients may need to be hospitalized to ensure
adequate hydration. The aim of this study was to assess the efficacy
and tolerability of a weekly schedule of docetaxel and cisplatin.
Patients and Methods: Patients with inoperable stage International
Union Against Cancer IIIB (malignant effusion) or IV non-small
cell lung cancer received docetaxel (35 mg/m2, 30 minutes infusion)
and cisplatin (25 mg/m2, 30 minutes infusion) on days 1, 8, and 15,
every 4 weeks for 4 to 6 cycles. Ondansetron (8 mg) and dexameth-
asone (8 mg) were given intravenously before chemotherapy. The
patients received oral dexamethasone 2  4 mg daily from the day
before until the day after chemotherapy. NK1-antagonists were
given at the investigator’s discretion. The majority of patients was
treated in outpatient departments. Safety was assessed using CTCAE
v3.0. The primary end point was response rate (RECIST).
Results: Forty-four patients were included. Twelve of 44 patients
achieved an objective response (11 partial, 1 complete, intent-to-
treat response rate 27%). Median time to progression was 4.4
months (95% confidence interval: 4.0–4.7) and median survival 9.6
months (95% confidence interval: 2.9–16.2). Patients received a
median of three full cycles. Four patients (9%) required dose
reductions. No cases of febrile neutropenia or grade 2 to 4 throm-
bocytopenia were observed. One patient (2%) experienced grade 3/4
nausea and vomiting.
Conclusions: Weekly docetaxel-cisplatin demonstrated comparable
efficacy with three-weekly schedules. Although the frequencies of
neutropenia and febrile neutropenia were low, non-neutropenic in-
fections remained a problem. Because of relatively short hydration,
the schedule can be safely administered in an outpatient setting.
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In recent years, the outcome of patients with local andlocally advanced non-small cell lung cancer (NSCLC) has
modestly improved. In the metastatic setting, improved pa-
tient selection and novel drugs have facilitated some advance,
although survival in most patients with advanced disease
remains very limited.1–3 As a result, treatment tolerability and
comfort of administration are gaining increased attention.
The recommended three-weekly schedule of docetaxel
and cisplatin is frequently associated with neutropenia and
subsequent neutropenic infections.1,3,4 Moreover, patients re-
ceiving full-dose cisplatin frequently require hospitalization
to ensure appropriate pretreatment and posttreatment hydra-
tion. Hospitalization has a substantial negative impact on
quality of life, which is important when considering the
dramatically shortened survival time of patients with ad-
vanced disease.
Weekly administration may facilitate outpatient admin-
istration of the combination. After Ohe et al.5 evaluated
maximum tolerable doses of weekly docetaxel/cisplatin in
their phase I study, phase II data were published by Niho et
al.6 in 2002 and by Ohe et al.7 in 2004 with efficacy results
comparable with those of three-weekly schedules. In this
study, we investigated the tolerability and efficacy of a
weekly schedule of docetaxel and cisplatin in the first-line
treatment of advanced NSCLC in Caucasian patients.
PATIENTS AND METHODS
This noncomparative, open-label phase II study was
performed in three medical centers in Germany, including
two pulmonologist departments and one hematology/oncol-
ogy department. The patients were accrued between August
2004 and September 2006.
Eligible patients had International Union Against Can-
cer stage IIIB (malignant effusion) or stage IV non-small cell
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lung cancer and were chemonaive. Eastern Cooperative On-
cology Group performance status had to be 2. Adequate
organ function was defined as absolute neutrophil counts
1.5  109/liter, platelet count 100  109/liter, and total
bilirubin 1.25  the upper limit of normal and plasma
creatinine within the normal limits. Brain metastases were not
excluded. All subjects signed informed consent before enter-
ing the study. The study protocol had been approved by the
responsible ethics committee at Charite´ Universita¨tsmedizin
Berlin, Germany.
Patients were treated with docetaxel (35 mg/m2, 30-
minute infusion) and cisplatin (25 mg/m2, 30-minute infu-
sion) on days 1, 8, and 15 of each 28-day cycle. The number
of scheduled cycles was 4 to 6 depending on the decision of
the local investigator. The treatment protocol specified a total
hydration volume of 2750 ml (including chemotherapy solu-
tions) delivered during 3.5 hours on each treatment day.
Ondansetron (8 mg) and dexamethasone (8 mg) were given
intravenously as premedication and 4 mg of dexamethasone
was administered orally twice daily from the day before until
the day after each chemotherapy. NK-1 antagonists were
administered at the local investigator’s discretion.
The primary end point was response to treatment (as-
sessed according to RECIST). The secondary end points
comprised median overall survival and 1-year survival, me-
dian time to progression, and toxicity (National Cancer In-
stitute Common Toxicity Criteria version 3.0).
A Simon two-stage optimal design was used.8 With  
0.05 and   1-0.80, a null hypothesized response rate of
0.20 and an alternative response rate of 0.40 were assumed.
Therefore, three responses were needed among the first 13
subjects (first stage) to proceed to the full accrual of 44
patients. The upper limit of second-stage rejection was 12
responses in the 44 evaluable patients.
RESULTS
Accrual and Administration of Treatment
Forty-four patients were enrolled, all of whom were
evaluable for safety. Forty patients received at least one full
cycle and were evaluated for efficacy. Baseline characteris-
tics are presented in Table 1. The majority of the patients was
treated in outpatient departments. The median number of full
cycles administered was 3. Seventeen patients (38.6%) re-
ceived 4 treatment cycles.
The chemotherapy dose had to be reduced in four
patients (9.1%). Reasons for reduction included nausea (one
patient), fatigue/asthenia (two patients), and frequent bron-
chopulmonary infections (one patient). Of the patients, 24,
14, four, one, and one had total delays of 0, 1, 2, 3, and 4
weeks during their treatment, respectively. The calculated
dose density per cycle was 92/92%, 90/90%, 90/91%, 91/
91% for cycles 1, 2, 3, and 4, respectively.
Response and Survival
In the intent-to-treat analysis, 12 patients (27.3%) dem-
onstrated a treatment response. One patient (2.3%) had a
complete response and 11 patients (25.0%) had a partial
response. Thus, the prespecified criteria for efficacy accord-
ing to the statistical model were not met (at least 13 respond-
ers required). Sixteen patients (36.4%) were observed as
having a stable disease. Progressive disease was observed in
eight patients (18.2%), and a further eight patients (18.2%)
were not evaluable for response.
The median overall survival time was 9.6 months (95%
confidence interval: 2.9–16.2), with 45.5% (n  20) of the
patients surviving for 1 year, median time to progression
was 4.4 months (95% confidence interval: 4.0–4.7). For
details see Figures 1 and 2.
Tolerability
Severe hematologic toxicity was rare, and no cases of
febrile neutropenia or grades 2 to 4 thrombocytopenia oc-
curred (Table 2). Only one patient (2%) experienced grade 3
nausea and vomiting, whereas mild nausea was common.
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FIGURE 1. Overall survival.
TABLE 1. Patient Baseline Characteristics
Characteristics N Percentage
Total patient number 44 100
Age (range, 46–74 yr; median, 62 yr)
65 yr, n (%) 13 29.5
70 yr, n (%) 6 13.6
Female 12 27.3
Tumor histology
Squamous cell carcinoma 13 29.5
Adenocarcinoma 23 52.3
Large cell carcinoma 2 4.5
Undifferentiated/other 6 13.6
Tumor UICC stage
IIIB 5 11.4
IV 39 88.6
WHO/ECOG performance status
0 10 22.7
1 27 61.4
2 7 15.9
UICC, International Union Against Cancer; WHO, World Health Organization;
ECOG, Eastern Cooperative Oncology Group.
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Moreover, several patients suffered from moderate to severe
fatigue (n  11 [25%] with grades 2–3).
Five patients (11%) died during therapy for reasons that
were not unequivocally attributable to tumor progression.
Causes of death included bacterial meningitis with normal
neutrophil counts (n 1), pneumonia with normal neutrophil
counts (n  1), suspected pulmonary arterial embolism (n 
1), diagnosed pulmonary arterial embolism (n  1), and
unknown cause (n  1; death at home and autopsy not
performed). Two patients (4%) died within 30 days after
inclusion. These patients were termed as early death (pulmo-
nary arterial embolism [n  1] and unknown cause [n  1]).
In addition, one patient suffered from a grade 4 infection with
normal neutrophil counts (pneumonia), and another seven
patients had non-neutropenic grade 2/3 infections (the major-
ity was with nonsevere pneumonia and tracheobronchitis).
Infections occurred both early and late during the course of
treatment.
DISCUSSION
In this study, we demonstrated that a regimen of do-
cetaxel and cisplatin administered weekly is feasible. The
relatively low hydration time and volume makes outpatient
administration easier than in schedules with three-weekly
cisplatin. Because we observed only 12 responses, the spec-
ified criteria for demonstrating efficacy (13 intent-to-treat
responders) was not met. Nevertheless, the response rate and
time-to-event measures for progression and survival were in
line with published three-weekly regimens with docetaxel
and cisplatin1,3,4 but were slightly inferior to other weekly
studies.6,7 In the studies published by Schiller et al.,1 Fossella
et al.,3 and Georgoulias et al.,4 the three-weekly docetaxel/
cisplatin objective response rates ranged from 17 to 36.5%.
Time to progression was in the range 3.7 to 5.5 months,
whereas overall median survival was between 7.4 and 11.3
months.
Phase I results on weekly schedules of docetaxel and
cisplatin were first published in 2001 by a Japanese group.5
With a fixed dose of 25 mg/m2 cisplatin, the docetaxel dose
was stepwise escalated. The docetaxel dose was up to 45
mg/m2 for patients 74 years of age and up to 25 mg/m2 for
patients 75 years of age when given as three consecutive
weekly treatments every 4 weeks. Dose-limiting toxicities
were neutropenia, infections, and asthenia/fatigue. The same
group conducted a phase II study in which the recommended
schedule for nonelderly patients (35 mg/m2 of docetaxel and
25 mg/m2 of cisplatin for three consecutive weekly treat-
ments every 4 weeks) was applied to a population of 37
patients with advanced NSCLC.6 Enrolled patients were 74
years of age and possessed a good performance status (East-
ern Cooperative Oncology Group 0 or 1). With an overall
response rate of 27% and a median survival of 12.8 months,
the combination provided comparable efficacy with three-
weekly schedules. Hematologic toxicity was unusual, and
none of the patients suffered from febrile neutropenia or
severe infections. Mild to moderate nausea and vomiting and
diarrhea were common nonhematologic adverse events. The
same investigators published further phase II data later in
20047 from a series of 34 elderly patients (75 years of age or
older). The basis of their treatment schedule was the recom-
mended dose from the former phase I study, in particular 20
mg/m2 of docetaxel and 25 mg/m2 of cisplatin for 3 consec-
utive weeks with 1 week off treatment. They observed ex-
cellent results with 52% response rate and a median overall
survival of 15.8 months. None of the patients suffered from
grade 3/4 infections, and severe nausea and vomiting was
only observed in one patient (3%).
The present chemotherapy schedule demonstrated low
hematologic toxicity. Leukopenia/neutropenia or febrile neu-
tropenia were uncommon. Only two patients (4%) suffered
from grade 3/4 neutropenia, whereas none of the subjects had
febrile neutropenia. In former studies with three-weekly ap-
plication of docetaxel and cisplatin, severe hematologic tox-
icity occurred more frequently. In the two largest study
populations treated with 75 mg/m2 of docetaxel and 75
mg/m2 of cisplatin every 3 weeks, 75/69% of the patients had
grades 3 and 4 neutropenia, respectively, and 5/10% devel-
oped febrile neutropenia.1,3 In the large study giving 100
mg/m2 of cisplatin and 80 mg/m2 of docetaxel every 3 weeks
(with primary prophylactic granulocyte-colony stimulating
factor support), 28% of the patients had grade 3/4 neutropenia
and 9% suffered from febrile neutropenia.4 Thus, in this
study, hematologic side effects were markedly reduced.
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FIGURE 2. Time to progression.
TABLE 2. Grade 3/4 Toxicities (National Cancer Institute
Common Toxicity Criteria version 3.0), n  44
Grade 3/4 Adverse Events N Percentage
Leukopenia/neutropenia 2 4.5
Neutropenic infections 0 0
Thrombocytopenia 0 0
Infection without neutropenia 2 4.5
Nausea and vomiting 1 2.3
Diarrhea 2 4.5
Fatigue/asthenia 3 6.8
Mucositis 1 2.3
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Moreover, severe nausea and vomiting were infrequently
observed, whereas a considerable number of patients com-
plained of milder nausea. Mild to moderate fatigue was also
common. Docetaxel is known for its potential to cause infections
without neutropenia. In a retrospective study conducted by
Souglakos et al.,9 docetaxel-based chemotherapy caused 2.4/2.8-
fold more nonneutropenic infections than with paclitaxel-based
or taxane-free schedules. This may be related to severe CD4-
lymphopenia. In this study, although we observed hardly any
high-grade neutropenia, two patients died of infections and one
had serious (grade 4) pneumonia. Other patients required oral
antibiotics during their course of chemotherapy for less serious
complications.
The weekly administration of chemotherapy may result
in higher doses of dexamethasone. The protocol comprised 9
days of high-dose dexamethasone in every 28-day cycle,
which may contribute to the development of infections.
Although additional corticosteroids to prevent or treat de-
layed nausea and vomiting were generally not necessary,
exposure is probably markedly higher than in three-weekly
schedules.
However, the treatment compliance of three full cycles
in median (12 weeks) was similar to other published studies
of docetaxel/cisplatin combinations (15/12 weeks/not re-
corded in the three-weekly schedules3,4,1 and 8/12 weeks in
the Japanese weekly studies6,7).
This study has certain limitations. In recent months,
study results that have become available contradict the par-
adigm of homogeneity of all non-small lung cancers under
chemotherapy.10 Therefore, from today’s point of view, the
relatively general selection criterion “non-small cell lung
cancer” seems to be suboptimal, and the particular histologies
possibly warrant more precise patient stratification. This was
unknown at the time of study initiation. With a relatively
low-dose density of 75 mg/m2/4 wk (18.75 mg/m2/wk) in this
study, cisplatin was obviously slightly underdosed when
compared with common three-weekly schedules. However,
this was not associated with clearly inferior efficacy or
advantages or disadvantages in compliance to treatment. The
data available from studies with weekly cisplatin and do-
cetaxel in advanced NSCLC are currently limited to Japanese
patients. Although this study confirms the observed low
hematologic toxicity, we were not able to confirm the ex-
traordinarily long survival previously mentioned in these
publications. From today’s viewpoint, it seems that Asian
populations include more light or never smokers and females
who have a favorable prognosis or exhibit a better outcome to
more novel targeted second-line agents.11,12
In summary, the combination of docetaxel and cisplatin
given weekly demonstrated less hematologic toxicity and
febrile neutropenia, whereas nonneutropenic infections re-
main a problem. Although the statistical needs for demon-
strating efficacy were not met, the efficacy was comparable
with three-weekly schedules when given as first-line chemo-
therapy for advanced NSCLC. Because hydration volumes
are relatively low with this schedule, safe outpatient admin-
istration is feasible.
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